A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

NCT06361888 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

502

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
DRUG: Nab-paclitaxel Plus Gemcitabine
DRUG: Surufatinib with Nab-paclitaxel, and Gemcitabine

Sponsor

Hutchmed